Identification of a potent and selective synthetic agonist at the CRTH2 receptor

Molecular Pharmacology

Volumn 67, Issue 6, 2005, Pages 1834-1839

  Gervais, François G ^a   Morello, Jean Pierre ^a   Beaulieu, Christian ^a   Sawyer, Nicole ^a   Denis, Danielle ^a   Greig, Gillian ^a   Malebranche, A Daniel ^a   O'Neill, Gary P ^a  

^a MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOATTRACTANT RECEPTOR HOMOLOGOUS MOLECULE EXPRESSED ON T HELPER TYPE 2 CELLS RECEPTOR; CHEMOATTRACTANT RECEPTOR HOMOLOGOUS MOLECULE EXPRESSED ON T HELPER TYPE 2 CELLS RECEPTOR AGONIST; G PROTEIN COUPLED RECEPTOR; L 888607; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; PROSTANOID RECEPTOR; UNCLASSIFIED DRUG; (9 ((4 CHLOROPHENYL)THIO) 6 FLUORO 2,3 DIHYDRO 1H PYRROLO(1,2 A)INDOL 1 YL)ACETIC ACID; (9-((4-CHLOROPHENYL)THIO)-6-FLUORO-2,3-DIHYDRO-1H-PYRROLO(1,2-A)INDOL-1-YL)ACETIC ACID; ACETIC ACID DERIVATIVE; DRUG DERIVATIVE; FUSED HETEROCYCLIC RINGS; IMMUNOGLOBULIN RECEPTOR; INDOMETACIN; LIGAND; PROSTAGLANDIN D2 RECEPTOR; PROSTAGLANDIN RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; ANIMAL; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECT; DRUG POTENTIATION; EOSINOPHIL; HUMAN; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; NEUTROPHIL CHEMOTAXIS; PHYSIOLOGY;

ACETIC ACIDS; ANIMALS; CHEMOTAXIS, LEUKOCYTE; EOSINOPHILS; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; INDOMETHACIN; LIGANDS; MALE; MICE; MICE, INBRED ICR; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN;

EID: 21744448211     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.104.009068     Document Type: Article

References (20)

1. Barnett J, Chow J, Ives D, Chiou M, Mackenzie R, Osen E, Nguyen B, Tsing S, Bach C, Freire J, et al. (1994) Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system. Biochim Biophys Acta 1209:130-139.
2. Bocher V, Pineda-Torra I, Fruchart JC, and Staels B (2002) PPARs: transcription factors controlling lipid and lipoprotein metabolism. Ann NY Acad Sci 967:7-18.
3. Cosmi L, Annunziato F, Galli MIG, Maggi RME, Nagata K, and Romagnani S (2000) CRTH2 is the most reliable marker for the detection of circulating human type 2 Th and type 2 T cytotoxic cells in health and disease. Eur J Immunol 30:2972-2979.
4. Fernandes B and Crankshaw D (1995) Functional characterization of the prostanoid DP receptor in human myometrium. Eur J Pharmacol 283:73-81.
5. Gervais FG, Cruz RP, Chateauneuf A, Gale S, Sawyer N, Nantel F, Metters KM, and O'Neill GP (2001) Selective modulation of chemokinesis, degranulation and apoptosis in eosinophils through the PGD2 receptors CRTH2 and DP. J Allergy Clin Immunol 108:982-988.
6. Hirai H, Tanaka K, Takano S, Ichimasa M, Nakamura M, and Nagata K (2002) Cutting edge: agonistic effect of indomethacin on a prostaglandin d2 receptor, CRTH2. J Immunol 168:981-985.
7. Hirai H, Tanaka K, Yoshie O, Ogawa K, Kenmotsu K, Takamori Y, Ichimasa M, Sugamura K, Nakamura M, Takano S, et al. (2001) Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils and basophils via seven-transmembrane receptor CRTH2. J Exp Med 193:255-261.
8. Liston TE and Roberts LJ (1985) Metabolic fate of radiolabeled prostaglandin d2 in a normal human male volunteer. J Biol Chem 260:13172-13180.
9. Monneret G, Gravel S, Diamond M, Rokach J, and Powell WS (2001) Prostaglandin D2 is a potent chemoattractant for human eosinophils that acts via a novel DP receptor. Blood 98:1942-1948.
10. Nagata K and Hirai H (2003) The second PGD(2) receptor CRTH2: structure, properties and functions in leukocytes. Prostaglandins Leukot Essent Fatty Acids 69:169-177.
11. Nagata K, Hirai H, Tanaka K, Ogawa K, Aso T, Sugamura K, Nakamura M, and Takano S (1999a) CRTH2, an orphan receptor of T-helper-2-cells, is expressed on basophils and eosinophils and responds to mast cell-derived factor(s). FEBS Lett 459:195-199.
12. Nagata K, Tanaka K, Ogawa K, Kemmotsu K, Imai T, Yoshie O, Abe H, Tada K, Nakamura M, Sugamura K, et al (1999b) Selective expression of a novel surface molecule by human Th2 cells in vivo. J Immunol 162:1278-1286.
13. Robinson C, Herbert CA, Bedwell S, Shell DJ, and Holgate ST (1989) The metabolism of prostaglandin D2. Evidence for the sequential conversion by NADPH and NAD+ dependent pathways. Biochem Pharmacol 38:3267-3271.
14. Sawyer N, Cauchon E, Chateauneuf A, Cruz RP, Nicholson DW, Metters KM, O'Neill GP, and Gervais FG (2002) Molecular pharmacology of the human prostaglandin D(2) receptor, CRTH2. Br J Pharmacol 137:1163-1172.
15. Sugimoto H, Shichijo M, Iino T, Manabe Y, Watanabe A, Shimazaki M, Gantner F, and Bacon KB (2003) An orally bioavailable small molecule antagonist of CRTH2, ramatroban (BAY u3405), inhibits prostaglandin D2-induced eosinophil migration in-vitro. J Pharmacol Exp Ther 305:347-352.
16. Tanaka K, Hirai H, Takano S, Nakamura M, and Nagata K (2004) Effects of prostaglandin D2 on helper T Cell functions. Biochem Biophys Res Commun 316:1009-1014.
17. Whittle BJ, Moncada S, Mullane K, and Vane JR (1983) Platelet and cardiovascular activity of the hydantoin BW245C, a potent prostaglandin analogue. Prostaglandins 25:205-223.
18. Woodward DF, Hawley SB, Williams LS, Ralston TR, Protzman CE, Spada CS, and Nieves AL (1990) Studies on the ocular pharmacology of prostaglandin D2. Investig Ophthalmol Vis Sci 31:138-146.
19. Wright DH, Metters KM, Abramovitz M, and Ford-Hutchinson AW (1998) Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist. Br J Pharmacol 123:1317-1324.
20. Yoshimura-Uchiyama C, Iikura M, Yamaguchi M, Nagase H, Ishii A, Matsushima K, Yamamoto K, Shichijo M, Bacon KB, and Hirai K (2004) Differential modulation of human basophil functions through prostaglandin D2 receptors DP and CRTH2/ DP2. Clin Exp Allergy 34:1283-1290.